Fischer, Charlotte Viola

[["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Investigative Ophthalmology & Visual Science"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Mans, Viktoria"],["dc.contributor.author","Fischer, Charlotte"],["dc.contributor.author","Khattab, Mohammed"],["dc.contributor.author","Wecker, Thomas"],["dc.date.accessioned","2018-11-07T10:08:43Z"],["dc.date.available","2018-11-07T10:08:43Z"],["dc.date.issued","2016"],["dc.identifier.isi","000394174001307"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39521"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Assoc Research Vision Ophthalmology Inc"],["dc.publisher.place","Rockville"],["dc.relation.conference","Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)"],["dc.relation.eventlocation","Seattle, WA"],["dc.relation.issn","1552-5783"],["dc.relation.issn","0146-0404"],["dc.title","12% fat milk as OCT contrast agent for ex vivo imaging."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","397"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Investigative Ophthalmology & Visual Science"],["dc.bibliographiccitation.lastpage","406"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Gottschalk, Hanna M."],["dc.contributor.author","Wecker, Thomas"],["dc.contributor.author","Khattab, Mohammed H."],["dc.contributor.author","Fischer, Charlotte V."],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Rehfeldt, Florian"],["dc.contributor.author","Lubjuhn, Roswitha"],["dc.contributor.author","Russmann, Christoph"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2019-07-09T11:50:10Z"],["dc.date.available","2019-07-09T11:50:10Z"],["dc.date.issued","2019"],["dc.description.abstract","Purpose: Contrast agents applicable for optical coherence tomography (OCT) imaging are rare. The intrascleral aqueous drainage system would be a potential application for a contrast agent, because the aqueous veins are of small diameter and located deep inside the highly scattering sclera. We tested lipid emulsions (LEs) as candidate OCT contrast agents in vitro and ex vivo, including milk and the anesthetic substance Propofol. Methods: Commercial OCT and OCT angiography (OCTA) devices were used. Maximum reflectivity and signal transmission of LE were determined in tube phantoms. Absorption spectra and light scattering was analyzed. The anterior chamber of enucleated porcine eyes was perfused with LEs, and OCTA imaging of the LEs drained via the aqueous outflow tract was performed. Results: All LEs showed a significantly higher reflectivity than water (P < 0.001). Higher milk lipid content was positively correlated with maximum reflectivity and negatively with signal transmission. Propofol exhibited the best overall performance. Due to a high degree of signal fluctuation, OCTA could be applied for detection of LE. Compared with blood, the OCTA signal of Propofol was significantly stronger (P = 0.001). As a proof of concept, time-resolved aqueous angiography of porcine eyes was performed. The three-dimensional (3D) structure and dynamics of the aqueous outflow were significantly different from humans. Conclusions: LEs induced a strong signal in OCT and OCTA. LE-based OCTA allowed the ability to obtain time-resolved 3D datasets of aqueous outflow. Possible interactions of LE with inner eye's structures need to be further investigated before in vivo application."],["dc.identifier.doi","10.1167/iovs.18-25223"],["dc.identifier.pmid","30682210"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15874"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59715"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1552-5783"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Lipid Emulsion-Based OCT Angiography for Ex Vivo Imaging of the Aqueous Outflow Tract."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4970"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Investigative Opthalmology & Visual Science"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Fischer, Charlotte V."],["dc.contributor.author","Mans, Viktoria"],["dc.contributor.author","Horn, Maren"],["dc.contributor.author","Naxer, Sabine"],["dc.contributor.author","Klettner, Alexa"],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2019-07-09T11:43:03Z"],["dc.date.available","2019-07-09T11:43:03Z"],["dc.date.issued","2016"],["dc.description.abstract","PURPOSE. Vascular endothelial growth factor–signaling in human tenon fibroblasts (hTFs) has recently become a target for antifibrotic treatment in glaucoma filtration surgery. The anti- VEGF antibody bevacizumab (BVC) has been shown to increase filtration bleb size. Given the relatively high concentration of BVC needed to obtain an effect, we investigated whether BVC acts through VEGF inhibition or via non–antigen-dependent ways. METHODS. Human tenon fibroblast primary cultures were obtained from strabismus surgery subjects. Under low (0.2%) and high (10%) serum conditions, cells were incubated with BVC, ranibizumab (RNB), aflibercept (AFB), or rituximab (RTX) at different concentrations. Total number of cells and number of dead or proliferating (5-bromo-2-deoxy-uridinepositive) cells were assessed after 24 hours. Concentrations of VEGF-A in cell culture media was measured with ELISA. Intracellular IgG was detected with immunostaining and Western blot analysis. RESULTS. In quiescent hTF culture (0.2% serum) the addition of 5 mg/mL BVC induced widespread cell death. Under proliferative conditions (10% serum), BVC reduced the number of proliferating cells. No such effect was observed with 2.5 mg/mL BVC or with 10 mg/mL AFB or 2.5 mg/mL RNB, although they were equally effective in binding free VEGF-A in the culture media. Instead, the CD20 antibody RTX, which did not bind VEGF, induced hTF death and inhibited proliferation in a BVC-comparable fashion. Bevacizumab, AFB, and RTX were detected intracellularly in a concentration-dependent manner. CONCLUSIONS. The cell death–inducing and antiproliferative effect of 5 mg/mL BVC appeared not to depend on VEGF inhibition. Our data question a direct role of VEGF for hTF survival and proliferation."],["dc.identifier.doi","10.1167/iovs.16-19938"],["dc.identifier.pmid","27654424"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14091"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58812"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1552-5783"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","The Antiproliferative Effect of Bevacizumab on Human Tenon Fibroblasts Is Not Mediated by Vascular Endothelial Growth Factor Inhibition"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]